Evidence map›Paper›PMID 39657243›Full record

ArticleCardiovascular research2025

NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway.

Anna Zoccarato, Ioannis Smyrnias, Christina M Reumiller, Anne D Hafstad, Mei Chong, Daniel A Richards, Celio X C Santos, Asjad Visnagri, Sharwari Verma, Daniel I Bromage and 5 more

Abstract read
In one paragraph

Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Anna ZoccaratoSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0003-0083-5430
Ioannis SmyrniasSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0001-6422-938X
Christina M ReumillerSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0001-9072-259X
Anne D HafstadSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0003-0711-9736
Mei ChongSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Daniel A RichardsSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Celio X C SantosSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Asjad VisnagriSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0003-0191-2629
Sharwari VermaSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Daniel I BromageSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0002-4243-5964
Min ZhangSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0003-1657-1337
Xiaohong ZhangSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Greta SawyerSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0003-2801-1900
Richard ThompsonSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.
Ajay M ShahSchool of Cardiovascular and Metabolic Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, James Black Centre,125 Coldharbour Lane, SE5 9NU London, UK.ORCID 0000-0002-6547-0631

Funding

British Heart Foundation RG/20/3/34823Fondation Leducq 17CVD04
6 · The paper itself

Abstract

aimsThe transcription factor nuclear factor erythroid-derived 2-like 2 (NRF2) is well recognized as a master regulator of antioxidant responses and cytoprotective genes. Previous studies showed that NRF2 enhances the resistance of mouse hearts to chronic haemodynamic overload, at least in part by reducing oxidative stress. Evidence from other tissues suggests that NRF2 may modulate glucose intermediary metabolism but whether NRF2 has such effects in the heart is unclear. Here, we investigate the role of NRF2 in regulating glucose intermediary metabolism and cardiac function during disease stress. METHODS AND

resultsCardiomyocyte-specific Keap1 knockout (csKeap1KO) mice, deficient in the endogenous inhibitor of NRF2, were used as a novel model of constitutively active NRF2 signalling. Targeted metabolomics and isotopomer analysis were employed in studies with 13C6-glucose in csKeap1KO and wild-type mice. Pharmacological and genetic approaches were utilized in neonatal rat ventricular myocytes (NRVMs) to explore molecular mechanisms. We found that cardiac-specific activation of NRF2 redirected glucose metabolism towards the pentose phosphate pathway (PPP), a branch pathway of glycolysis, and mitigated pressure overload-induced cardiomyocyte death and cardiac dysfunction. Activation of NRF2 also protected against myocardial infarction-induced DNA damage in remote myocardium and cardiac dysfunction. In vitro, knockdown of Keap1 upregulated PPP enzymes and reduced cell death in NRVM subjected to chronic neurohumoral stimulation. These pro-survival effects were abolished by pharmacological inhibition of the PPP or silencing of the PPP rate-limiting enzyme glucose-6-phosphate dehydrogenase. Knockdown of NRF2 in NRVM increased stress-induced DNA damage, which was rescued by supplementing the cells with either nicotinamide adenine dinucleotide phosphate (NADPH) or nucleosides, the two main products of the PPP.

conclusionThese results indicate that NRF2 regulates cardiac metabolic reprogramming by stimulating the diversion of glucose into the PPP, thereby generating NADPH and providing nucleotides to prevent stress-induced DNA damage and cardiac dysfunction.

Indexed as

GlucoseMyocytes, CardiacNF-E2-Related Factor 2Pentose Phosphate PathwayAnimalsCells, CulturedDisease Models, AnimalGlycolysisKelch-Like ECH-Associated Protein 1MaleMetabolic ReprogrammingMiceMice, Inbred C57BLMice, KnockoutOxidative StressRatsGlucoseKeap1 protein, mouseKEAP1 protein, ratKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseNF-E2-Related Factor 2Cardiac dysfunctionGlucose metabolismMetabolomicsNuclear factor erythroid–derived 2-like 2 (NRF2)Pentose phosphate pathway

Identifiers

PMID39657243
PMCPMC12012450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.